AIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 30,865 Shares

AIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III acquired 30,865 shares of the business’s stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $0.41 per share, for a total transaction of $12,654.65. Following the purchase, the chief operating officer now directly owns 212,583 shares of the company’s stock, valued at $87,159.03. The transaction was disclosed in a filing with the SEC, which is available through this link.

AIM ImmunoTech Trading Up 1.2 %

Shares of NYSE AIM opened at $0.43 on Wednesday. The business has a 50 day simple moving average of $0.43 and a 200-day simple moving average of $0.44. AIM ImmunoTech Inc. has a twelve month low of $0.32 and a twelve month high of $0.75. The company has a market capitalization of $21.57 million, a price-to-earnings ratio of -0.71 and a beta of -0.11.

AIM ImmunoTech (NYSE:AIM) last released its earnings results on Friday, March 29th. The company reported ($0.26) earnings per share for the quarter. AIM ImmunoTech had a negative net margin of 14,337.62% and a negative return on equity of 121.69%. The business had revenue of $0.07 million for the quarter.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).